These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 32090746)

  • 1. A multi-national, multi-disciplinary Delphi consensus study on using omega-3 polyunsaturated fatty acids (n-3 PUFAs) for the treatment of major depressive disorder.
    Guu TW; Mischoulon D; Sarris J; Hibbeln J; McNamara RK; Hamazaki K; Freeman MP; Maes M; Matsuoka YJ; Belmaker RH; Marx W; Pariante C; Berk M; Jacka F; Su KP
    J Affect Disord; 2020 Mar; 265():233-238. PubMed ID: 32090746
    [TBL] [Abstract][Full Text] [Related]  

  • 2. International Society for Nutritional Psychiatry Research Practice Guidelines for Omega-3 Fatty Acids in the Treatment of Major Depressive Disorder.
    Guu TW; Mischoulon D; Sarris J; Hibbeln J; McNamara RK; Hamazaki K; Freeman MP; Maes M; Matsuoka YJ; Belmaker RH; Jacka F; Pariante C; Berk M; Marx W; Su KP
    Psychother Psychosom; 2019; 88(5):263-273. PubMed ID: 31480057
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Omega-3 polyunsaturated fatty acids (n-3 PUFAs), somatic and fatigue symptoms in cardiovascular diseases comorbid major depressive disorder (MDD): A randomized controlled trial.
    Chang JP; Chang SS; Chen HT; Chien YC; Yang HT; Huang SY; Tseng PT; Chang CH; Galecki P; Su KP
    Brain Behav Immun; 2023 Aug; 112():125-131. PubMed ID: 37301235
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-dose omega-3 polyunsaturated fatty acid supplementation might be more superior than low-dose for major depressive disorder in early therapy period: a network meta-analysis.
    Luo XD; Feng JS; Yang Z; Huang QT; Lin JD; Yang B; Su KP; Pan JY
    BMC Psychiatry; 2020 May; 20(1):248. PubMed ID: 32434488
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Omega-3 polyunsaturated fatty acids in cardiovascular diseases comorbid major depressive disorder - Results from a randomized controlled trial.
    Chang JP; Chang SS; Yang HT; Chen HT; Chien YC; Yang B; Su H; Su KP
    Brain Behav Immun; 2020 Mar; 85():14-20. PubMed ID: 30902738
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Revision on the Effectiveness of Omega-3 Polyunsaturated Fatty Acids as Monotherapy in the Treatment of Major Depressive Disorder.
    Accinni T; Panfili M; Tarsitani L; Biondi M; Pasquini M; Maraone A
    Int J Clin Pract; 2022; 2022():3801235. PubMed ID: 36474548
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low omega-3 polyunsaturated fatty acids predict reduced response to standard antidepressants in patients with major depressive disorder.
    Cussotto S; Delgado I; Oriolo G; Kemper J; Begarie D; Dexpert S; Sauvant J; Leboyer M; Aouizerate B; Martin-Santos R; Schaefer M; Capuron L
    Depress Anxiety; 2022 May; 39(5):407-418. PubMed ID: 35357051
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Omega-3 polyunsaturated fatty acids for major depressive disorder.
    Su KP; Wang SM; Pae CU
    Expert Opin Investig Drugs; 2013 Dec; 22(12):1519-34. PubMed ID: 24083675
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Eicosapentaenoic and docosahexaenoic acids have different effects on peripheral phospholipase A2 gene expressions in acute depressed patients.
    Su KP; Yang HT; Chang JP; Shih YH; Guu TW; Kumaran SS; Gałecki P; Walczewska A; Pariante CM
    Prog Neuropsychopharmacol Biol Psychiatry; 2018 Jan; 80(Pt C):227-233. PubMed ID: 28648567
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasma phospholipid n-3 polyunsaturated fatty acids and major depressive disorder in Japanese elderly: the Japan Public Health Center-based Prospective Study.
    Hamazaki K; Matsuoka YJ; Yamaji T; Sawada N; Mimura M; Nozaki S; Shikimoto R; Tsugane S
    Sci Rep; 2021 Feb; 11(1):4003. PubMed ID: 33597590
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Meta-analysis and meta-regression of omega-3 polyunsaturated fatty acid supplementation for major depressive disorder.
    Mocking RJ; Harmsen I; Assies J; Koeter MW; Ruhé HG; Schene AH
    Transl Psychiatry; 2016 Mar; 6(3):e756. PubMed ID: 26978738
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low unesterified:esterified eicosapentaenoic acid (EPA) plasma concentration ratio is associated with bipolar disorder episodes, and omega-3 plasma concentrations are altered by treatment.
    Saunders EF; Reider A; Singh G; Gelenberg AJ; Rapoport SI
    Bipolar Disord; 2015 Nov; 17(7):729-42. PubMed ID: 26424416
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Disentangling the Molecular Mechanisms of the Antidepressant Activity of Omega-3 Polyunsaturated Fatty Acid: A Comprehensive Review of the Literature.
    Kalkman HO; Hersberger M; Walitza S; Berger GE
    Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33922396
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Omega-3 polyunsaturated fatty acid (PUFA) status in major depressive disorder with comorbid anxiety disorders.
    Liu JJ; Galfalvy HC; Cooper TB; Oquendo MA; Grunebaum MF; Mann JJ; Sublette ME
    J Clin Psychiatry; 2013 Jul; 74(7):732-8. PubMed ID: 23945451
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nutritional Neuroscience as Mainstream of Psychiatry: The Evidence- Based Treatment Guidelines for Using Omega-3 Fatty Acids as a New Treatment for Psychiatric Disorders in Children and Adolescents.
    Chang JP; Su KP
    Clin Psychopharmacol Neurosci; 2020 Nov; 18(4):469-483. PubMed ID: 33124582
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Abnormalities in the fatty acid composition of the postmortem entorhinal cortex of patients with schizophrenia, bipolar disorder, and major depressive disorder.
    Hamazaki K; Hamazaki T; Inadera H
    Psychiatry Res; 2013 Nov; 210(1):346-50. PubMed ID: 23731984
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Corrigendum to "A multi-national, multi-disciplinary Delphi consensus study on using omega-3 polyunsaturated fatty acids (n-3 PUFAs) for the treatment of major depressive disorder". [J Affect Disord. 15 (2020) 233-238].
    Guu TW; Mischoulon D; Sarris J; Hibbeln J; McNamara RK; Hamazaki K; Freeman MP; Maes M; Matsuoka YJ; Belmaker RH; Marx W; Pariante C; Berk M; Jacka F; Su KP
    J Affect Disord; 2020 Sep; 274():1226-1227. PubMed ID: 32663964
    [No Abstract]   [Full Text] [Related]  

  • 18. Fatty acids and recurrence of major depressive disorder: combined analysis of two Dutch clinical cohorts.
    Thesing CS; Lok A; Milaneschi Y; Assies J; Bockting CLH; Figueroa CA; Giltay EJ; Penninx BWJH; Ruhé HG; Schene AH; Bot M; Mocking RJT
    Acta Psychiatr Scand; 2020 Apr; 141(4):362-373. PubMed ID: 31785112
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Erythrocyte polyunsaturated fatty acid composition is associated with depression and FADS genotype in Caucasians.
    Cribb L; Murphy J; Froud A; Oliver G; Bousman CA; Ng CH; Sarris J
    Nutr Neurosci; 2018 Oct; 21(8):589-601. PubMed ID: 28552045
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Omega-3 polyunsaturated fatty acid supplementation and white matter changes in major depression.
    Chhetry BT; Hezghia A; Miller JM; Lee S; Rubin-Falcone H; Cooper TB; Oquendo MA; Mann JJ; Sublette ME
    J Psychiatr Res; 2016 Apr; 75():65-74. PubMed ID: 26802812
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.